Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients

International Journal of Neuroscience

Volumn 126, Issue 1, 2016, Pages 20-24

  Kumar, Rajeev ^a   Hauser, Robert A ^b   Mostillo, Joseph ^c   Dronamraju, Nalina ^c   Graf, Ana ^c   Merschhemke, Martin ^c   Kenney, Christopher ^c  

^a Colorado Neurological Institute ^*  (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

AFQ056; dyskinesia; levodopa; mavoglurant; Parkinson's disease

Indexed keywords

LEVODOPA; MAVOGLURANT; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; GLUK1 KAINATE RECEPTOR; INDOLE DERIVATIVE; KAINIC ACID RECEPTOR;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; LEVODOPA-INDUCED DYSKINESIA; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; TREMOR; UNIFIED DYSKINESIA RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG POTENTIATION; EARLY TERMINATION OF CLINICAL TRIAL; MIDDLE AGED; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EARLY TERMINATION OF CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, KAINIC ACID; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 84949322280     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.841685     Document Type: Article

References (12)

1. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89.
2. Hauser RA, McDermott MP, Messing S, for the Parkinson Study Group. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-60.
3. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327-29.
4. Cristina S, Zangaglia R, Mancini F, et al. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003;26:146-50.
5. Chase TN, Bibbiani F. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003; 5:139-46.
6. Samadi P, Gregoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-51.
7. Mela F, Marti M, Dekundy A, et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPAinduced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007; 101:483-97.
8. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-50.
9. Stocchi F, Destee A, Hattori N, et al. A 13-week, doubleblind, placebo-controlled study of AFQ056, ametabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa-induced dyskinesias. Abstract at the 15th International Congress of Parkinson's Disease and Movement Disorders, Toronto, Canada, June 5-9, 2011.
10. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
11. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebocontrolled trial. Mov Disord 2007;22:179-86.
12. Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011;26:813-18.